Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.
Actively Recruiting
Researchers are evaluating DT120, a psychoactive drug acting mainly on serotonin 2A receptors, for treating adults aged 18 to 74 with major depressive disorder MDD. This Phase 3 trial compares DT120 to placebo over 12 weeks in a double-blind, randomized, and triple-blind design to assess its efficacy and safety. Participants must have a confirmed diagnosis of MDD with specific symptom severity and duration, without major psychiatric or unstable medical conditions. The study includes a 12-week double-blind period where participants receive a single dose of either DT120 at one of two dose levels or placebo. This is followed by a 40-week open-label extension phase where all participants may receive DT120 with monitoring for retreatment based on safety and symptoms. The trial evaluates multiple outcomes related to depression severity, symptom improvement, anxiety, sexual function, quality of life, and work productivity. Participants will undergo regular assessments including depression rating scales like MADRS and CGI, anxiety scales, and questionnaires on sexual functioning and daily activity impact. Monitoring continues throughout the extension phase to assess treatment durability and response. The total participation may last up to 52 weeks, with evaluations at several timepoints to understand treatment effects and safety over both study phases.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elismetrep compared with a placebo for treating acute migraine attacks. This randomized, double-blind, phase III trial is conducted at multiple outpatient centers and sponsored by TriGemX Bio, Inc. The study focuses on adults aged 18 to 75 years who experience moderate to severe migraines lasting 4 to 72 hours, with a history of at least 2 but no more than 10 migraine attacks per month. Participants are randomly assigned to one of three groups elismetrep 10 mg, elismetrep 20 mg, or placebo. All treatments are taken orally during a migraine attack. The trial uses a parallel study design and is triple-blinded to ensure unbiased results. The main study period extends until February 2027, with participants monitored for responses two hours after dosing. During the study, participants will complete questionnaires and use an electronic diary on their smartphones to track migraine symptoms and treatment effects. Researchers will assess outcomes such as pain freedom, relief from bothersome symptoms, and functional disability at two hours post-dose. Additional evaluations include monitoring for adverse events up to eight days after dosing. Participants must follow the study schedule and complete all trial procedures to help assess elismetreps potential as an acute migraine treatment.
Actively Recruiting
Researchers are evaluating the effectiveness of osavampator compared to a placebo as an additional treatment to delay the return of depressive symptoms in adults with major depressive disorder MDD. This Phase 3 study focuses on maintaining treatment effects in participants diagnosed with recurrent moderate or severe MDD or persistent depressive disorder who have not responded adequately to oral antidepressants. The study aims to understand whether osavampator can help prevent relapse in this population. Participants will first receive osavampator during an initial open-label treatment phase. Following this, they will be randomly assigned to receive either osavampator or a matching placebo during a double-blind maintenance period. Both treatments are given as oral tablets, and participants will continue their existing oral antidepressants at the same dose and frequency throughout the study. The study may last up to approximately 32 months from randomization. During the study, participants will be regularly monitored for relapse of depressive symptoms using the Hamilton Depression Rating Scale. Researchers will track the time from randomization to relapse or the end of the study to assess treatment maintenance. Safety and adherence will be evaluated throughout, with participants expected to comply with study procedures and restrictions. The total duration of participation varies but can extend up to nearly three years.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, and immune response to the RSVpreF vaccine in healthy adults aged 60 years and older. This study includes participants from China and the United States, comparing reactions and antibody responses between those receiving RSVpreF and a placebo in China, while all participants in the US receive RSVpreF. The goal is to understand the effects and immune protection that the vaccine may provide to older adults. Participants will receive a single dose of either the RSVpreF vaccine or placebo in China or only RSVpreF in the US. The study includes a screening visit, followed by vaccination at Visit 1. Subsequent follow-ups include a telephone or clinic visit one week later to assess local and systemic reactions, a clinic visit one month after vaccination for health checks and blood tests, and a final telephone or clinic visit six months after vaccination to monitor overall health. Throughout the study, participants will have blood tests at screening China only, on vaccination day, and one month post-vaccination to measure antibody levels. Researchers will monitor local injection site reactions, systemic symptoms, adverse events, and newly diagnosed chronic medical conditions for up to six months. Participants will be involved in electronic diary recording and regular follow-up visits during the approximately six-month participation period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new form of LASIK called Ray Tracing Guided LASIK by comparing it to three other types of corneal refractive surgery KeratoLenticule Extraction KLEx using the Zeiss Visumax 800 Laser, Wavefront Optimized LASIK WFO LASIK using the Alcon EX500 Laser, and Topography Guided LASIK Contoura LASIK also using the Alcon EX500 Laser. The study focuses on patients with myopia or myopia with astigmatism and aims to compare visual outcomes across these different technologies in a prospective, randomized design. This study is conducted in three phases, each including at least 44 participants who undergo surgery for refractive correction. In each phase, patients will have one eye treated with Ray Tracing Guided LASIK and the other eye treated with one of the three comparator procedures. The surgeries use specific laser devices and technologies tailored to each method. Participants will receive routine postoperative care and medications as per standard practices. Participants will attend follow-up visits at 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery. At several visits, including screening and postoperative timepoints, patients will complete questionnaires about their experience. Researchers will measure uncorrected visual acuity at 3, 6, and 12 months as the main outcome. Additional assessments include predictability of vision correction. Retreatments are allowed only after all study visits are completed or the subject has left the study.
Actively Recruiting
Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial involves participants who have experienced PTSD symptoms for at least six months and have previously tried pharmacological or trauma-focused psychotherapy treatments. The study aims to assess how different doses of TSND-201 compare to a placebo in managing PTSD symptoms. Participants will be randomly assigned to one of three groups two groups receiving different doses of TSND-201 capsules, and one group receiving placebo capsules. These capsules are taken orally once a week for four consecutive weeks during the Treatment Period. After completing this period, participants will enter an 8-week Follow-up Period to monitor their progress and any lasting effects. Throughout the study, participants will undergo evaluations including the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD severity. Researchers will monitor safety and efficacy over up to 12 weeks. The study includes regular assessments and questionnaires to track symptoms and wellbeing during and after treatment.
Actively Recruiting
Evaluation of TSND-201 Capsules Versus Placebo for Treating Post Traumatic Stress Disorder in Adults
Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.
Actively Recruiting
Researchers are evaluating the effects and safety of solriamfetol in adults with binge eating disorder BED. This Phase 3 trial compares two doses of solriamfetol 150 mg and 300 mg with a placebo to better understand their impact on BED symptoms. Participants must be aged 18 to 55 with a diagnosis of BED based on DSM-5 criteria. Participants will be randomly assigned to one of three groups receiving either solriamfetol 150 mg, solriamfetol 300 mg, or placebo tablets, all taken once daily for 12 weeks. This randomized, double-blind study will assess how these treatments affect binge eating episodes over the course of the trial. During the 12 weeks, participants will be monitored for changes in the number of binge eating episodes. Safety and efficacy will be evaluated through regular assessments. All study-related care, including medication and visits, will be provided at no cost, and the total participation duration is approximately 12 weeks.
1-10 of 17
1